Danielle Akemi Bergara Kuramoto

Danielle Akemi Bergara Kuramoto

Auto-generated profile, based on publicly available information

Danielle Akemi Bergara Kuramoto

Universidade Federal de São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Sao Paulo Medical Journal
Verified
Journal Article
Open access
RCRebeca Mangabeira Correia
Rebeca Mangabeira Correia
BSBrena Costa Santos
Brena Costa Santos
ACAna Alyra Garcia Carvalho
Ana Alyra Garcia Carvalho
LALibnah Leal Areias
Libnah Leal Areias
DKDanielle Akemi Bergara Kuramoto
Danielle Akemi Bergara Kuramoto
LNLuis Carlos Uta Nakano
Luis Carlos Uta Nakano
Although an association has been made between coronavirus disease 2019 (COVID-19) and microvascular disease, data on vascular complications (other than venous thromboembolism) are sparse. To investigate the vascular complications in severely ill patients hospitalized with COVID-19 and their association with all-cause mortality. This cohort study was conducted at the Universidade Federal de São Paulo, Brazil. All 305 consecutive patients diagnosed with COVID-19 and hospitalized in the intensive care unit (ICU) of a tertiary university hospital from April 2 to July 17, 2021, were included and followed up for 30 days. Of these, 193 (63.3%) were male, and the mean age was 59.9 years (standard deviation = 14.34). The mortality rate was 56.3% (172 patients), and 72 (23.6%) patients developed at least one vascular complication during the follow-up period. Vascular complications were more prevalent in the non-survivors (28.5%) than in the survivors (17.3%) group and included disseminated intravascular coagulation (DIC, 10.8%), deep vein thrombosis (8.2%), acrocyanosis (7.5%), and necrosis of the extremities (2%). DIC (adjusted odds ratio (aOR) 2.30, 95% confidence interval (CI) 1.01–5.24, P = 0.046) and acrocyanosis (aOR 5.21, 95% CI 1.48–18.27, P = 0.009) were significantly more prevalent in the non-survivors than in the survivors group. Vascular complications in critically ill COVID-19 patients are common (23.6%) and can be closely related to the mortality rate (56.3%) until 30 days after ICU admission. Macrovascular complications have direct implications for mortality, which is the main outcome of the management of COVID-19. RBR-4qjzh7 (https://ensaiosclinicos.gov.br/rg/RBR-4qjzh7).

1 January 2021 in Jornal Vascular Brasileiro
Verified
Journal Article
Open access
ACAna Alyra Garcia Carvalho
Ana Alyra Garcia Carvalho
AAAna Laura e Silva Aidar
Ana Laura e Silva Aidar
BSBrena Costa dos Santos
Brena Costa dos Santos
DKDanielle Akemi Bergara Kuramoto
Danielle Akemi Bergara Kuramoto
MPMariana Raffo Pereda
Mariana Raffo Pereda
JAJorge Eduardo Amorim
Jorge Eduardo Amorim
Resumo Desde a classificação da doença por coronavírus 2019 (COVID-19) como pandemia pela Organização Mundial de Saúde (OMS), muitas medidas foram propostas com o intuito de diminuir os riscos e a chance de contaminação pelo novo coronavírus. Nesse contexto, o uso de equipamentos de proteção individual (EPIs) é de suma importância, especialmente em ambientes hospitalares e em situações que envolvem o cuidado em saúde, visto que o grau de exposição é notadamente maior no subgrupo de profissionais de saúde. Este artigo tem como objetivo propor um roteiro de uso de EPIs para procedimentos cirúrgicos. As recomendações sugeridas são estruturadas com base nas diretrizes do Ministério da Saúde e da OMS, e cinco roteiros de uso de EPIs foram sugeridos para os procedimentos mais comumente realizados: passagem de acesso venoso central; passagem de cateteres que necessitem de escopia; cirurgias abertas; angiografia diagnóstica e terapêutica; e curativos.

1 January 2023 in Revista do Colégio Brasileiro de Cirurgiões
Verified
Journal Article
Open access
DKDanielle Akemi Bergara Kuramoto
Danielle Akemi Bergara Kuramoto
LZLuiz Fernando Santetti Zanin
Luiz Fernando Santetti Zanin
RFRonald Luiz Gomes Flumignan
Ronald Luiz Gomes Flumignan
CFCarolina Dutra Queiroz Flumignan
Carolina Dutra Queiroz Flumignan
MRMarcello Erich Reicher
Marcello Erich Reicher
LNLuís Carlos Uta Nakano
Luís Carlos Uta Nakano
Background: peripheral arterial disease has smoking as its main avoidable vascular risk factor. However, most studies do not focus on smoking as the main exposure variable. Objectives: to assess the impact of smoking cessation interventions versus active comparator, placebo or no intervention, on peripheral arterial disease outcomes. Methods: we will use the Cochrane Handbook for Systematic Reviews of Interventions to guide whole this review process. We will consider parallel or cluster-randomised controlled trials (RCTs), quasi-RCTs, and cohort studies. We will search CENTRAL, MEDLINE, Embase, PsycINFO, LILACS and IBECS. We will also conduct a search of ClinicalTrials.gov and the ICTRP for ongoing or unpublished trials. Each research step will involve at least two independent reviewers. We will create a table, using GRADE pro GDT software, reporting the pooled effect estimates for the following outcomes: all-cause mortality, lower limb amputation, adverse events, walking distance, clinical severity, vessel or graft secondary patency, and QoL. Conclusions: we will assess these outcomes according to the five GRADE considerations to assess the certainty of the body of evidence for these outcomes, and to draw conclusions about the certainty of the evidence within the review.

14 March 2022 in Sao Paulo Medical Journal
Verified
Journal Article
Open access
HNHenrique Jorge Guedes Neto
Henrique Jorge Guedes Neto
DKDanielle Akemi Bergara Kuramoto
Danielle Akemi Bergara Kuramoto
RCRebeca Mangabeira Correia
Rebeca Mangabeira Correia
BSBrena Costa Santos
Brena Costa Santos
ABAmanda da Cunha Borges
Amanda da Cunha Borges
JBJosé Carlos Costa Baptista-Silva
José Carlos Costa Baptista-Silva
BACKGROUND: Congenital vascular anomalies and hemangiomas (CVAH) such as infantile hemangiomas, port-wine stains and brain arteriovenous malformations (AVMs) impair patients' lives and may require treatment if complications occur. However, a great variety of treatments for those conditions exist and the best interventions remain under discussion. OBJECTIVE: To summarize Cochrane systematic review (SR) evidence on treatments for CVAH. DESIGN AND SETTING: Review of SRs conducted in the Division of Vascular and Endovascular Surgery of Universidade Federal de Sao Paulo, Brazil. METHODS: A broad search was conducted on March 9, 2021, in the Cochrane Database of Systematic Reviews to retrieve any Cochrane SRs that assessed treatments for CVAH. The key characteristics and results of all SRs included were summarized and discussed. RESULTS: A total of three SRs fulfilled the inclusion criteria and were presented as a qualitative synthesis. One SR reported a significant clinical reduction of skin redness by at least 20%, with more pain, among 103 participants with port-wine stains. One SR reported that propranolol improved the likelihood of clearance 13 to 16-fold among 312 children with hemangiomas. One SR reported that the relative risk of death or dependence was 2.53 times greater in the intervention arm than with conservative management, among 218 participants with brain AVMs. CONCLUSION: Cochrane reviews suggest that treatment of port-wine stains with pulsed-dye laser improves redness; propranolol remains the best option for infantile hemangiomas; and conservative management seems to be superior to surgical intervention for treating brain AVMs.

29 April 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
AGAmanda Alves Assis Garcia
Amanda Alves Assis Garcia
AVAlexia Gabriela da Silva Vieira
Alexia Gabriela da Silva Vieira
DKDanielle Akemi Bergara Kuramoto
Danielle Akemi Bergara Kuramoto
ILIlana Gomes Leite
Ilana Gomes Leite
TFThais Rodrigues de Freitas
Thais Rodrigues de Freitas
LNLuis Carlos Uta Nakano
Luis Carlos Uta Nakano
Introduction Congenital heart disease (CHD) comprises the anatomic malformations that jeopardise the structure and function of the heart. It can be extremely complex and serious, corresponding to 30% of all deaths in the first month of life. The surgical approach for adequate treatment requires postoperative mechanical ventilation. The most critical decision related to the postoperative management of patients submitted to cardiac surgery is the right time for extubation, especially because not only abrupt or inadequate discontinuation of ventilatory support can lead to clinical decline and necessity of reintubation but also extended time of mechanical ventilation, which can lead to complications, such as pneumonia, atelectasis, diaphragm hypertrophy, and increasing morbidity and mortality. Methods and analysis This systematic review plans to include individual parallel, cross-over and cluster randomised controlled trials regarding any breathing trial test to predict extubation success in children submitted to cardiac surgery due to CHD. Studies with paediatric patients submitted to cardiac surgery for congenital cardiopathy repair, attended at a critical care unit, and under mechanical ventilatory support will be included. The main outcomes analysed will be success of extubation, reduction of pulmonary complications and time reduction of mechanical ventilation. Ethics and dissemination We will not treat patients directly; therefore, ethics committee approval was not necessary because it is not a primary study. We expect that this study may improve healthcare and medical assistance, helping healthcare professionals with routine daily decisions regarding the correct time for extubation. PROSPERO registration number CRD42021223999.

10 May 2021 in Archives of Disease in Childhood - Fetal and Neonatal Edition
Verified
Journal Article
Closed access
PDF file
BSBrena Costa Santos
Brena Costa Santos
RCRebeca Falcao Borja de Oliveira Correia
Rebeca Falcao Borja de Oliveira Correia
DKDanielle Akemi Bergara Kuramoto
Danielle Akemi Bergara Kuramoto
ACAna Alyra Garcia Carvalho
Ana Alyra Garcia Carvalho
RARafael Bernardes Avila
Rafael Bernardes Avila
LNLuis Carlos Uta Nakano
Luis Carlos Uta Nakano